Cargando…
A preclinical model of chronic pancreatitis driven by trypsinogen autoactivation
Inflammatory diseases of the pancreas have no specific therapy. Discovery of the genetic basis of chronic pancreatitis identified the digestive enzyme trypsin as a therapeutic target. Preclinical testing of trypsin inhibition has been hampered by the lack of animal models. Here we report the T7D23A...
Autores principales: | Geisz, Andrea, Sahin-Tóth, Miklós |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261995/ https://www.ncbi.nlm.nih.gov/pubmed/30487519 http://dx.doi.org/10.1038/s41467-018-07347-y |
Ejemplares similares
-
Engineering mouse cationic trypsinogen for rapid and selective activation by cathepsin B
por: Demcsák, Alexandra, et al.
Publicado: (2019) -
Trypsinogen isoforms in the ferret pancreas
por: Hegyi, Eszter, et al.
Publicado: (2018) -
Misfolding-induced chronic pancreatitis in CPA1 N256K mutant mice is unaffected by global deletion of Ddit3/Chop
por: Németh, Balázs Csaba, et al.
Publicado: (2022) -
Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan
por: Yasuda, Hiroaki, et al.
Publicado: (2019) -
The autoactivation of rabbit hageman factor
por: Wiggins, RC, et al.
Publicado: (1979)